# Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia

> **NCT00141141** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 383 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00141141
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2021-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141141, "Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00141141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*